22 35

Cited 0 times in

Interim Guidelines on Antiviral Therapy for COVID-19

DC FieldValueLanguage
dc.contributor.author구남수-
dc.contributor.author염준섭-
dc.contributor.author정수진-
dc.date.accessioned2021-01-19T08:14:33Z-
dc.date.available2021-01-19T08:14:33Z-
dc.date.issued2020-06-
dc.identifier.issn2093-2340-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181526-
dc.description.abstractSince the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure. As COVID-19 has such varied clinical manifestations and case fatality rates, no standard antiviral therapy regimen has been established other than supportive therapy. In the present guideline, we aim to introduce potentially helpful antiviral and other drug therapies based on in vivo and in vitro research and clinical experiences from many countries.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean, English-
dc.publisher대한감염학회-
dc.relation.isPartOfINFECTION AND CHEMOTHERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleInterim Guidelines on Antiviral Therapy for COVID-19-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSun Bean Kim-
dc.contributor.googleauthorKyungmin Huh-
dc.contributor.googleauthorJung Yeon Heo-
dc.contributor.googleauthorEun Jeong Joo-
dc.contributor.googleauthorYoun Jeong Kim-
dc.contributor.googleauthorWon Suk Choi-
dc.contributor.googleauthorYae Jean Kim-
dc.contributor.googleauthorYu Bin Seo-
dc.contributor.googleauthorYoung Kyung Yoon-
dc.contributor.googleauthorNam Su Ku-
dc.contributor.googleauthorSu Jin Jeong-
dc.contributor.googleauthorSung Han Kim-
dc.contributor.googleauthorKyong Ran Peck-
dc.contributor.googleauthorJoon Sup Yeom-
dc.identifier.doi10.3947/ic.2020.52.2.281-
dc.contributor.localIdA00189-
dc.contributor.localIdA02353-
dc.contributor.localIdA02353-
dc.contributor.localIdA03638-
dc.contributor.localIdA03638-
dc.relation.journalcodeJ01053-
dc.identifier.eissn2092-6448-
dc.identifier.pmid32342676-
dc.subject.keywordAntiviral-
dc.subject.keywordCOVID-19-
dc.subject.keywordSARS-CoV-2-
dc.subject.keywordTreatment-
dc.contributor.alternativeNameKu, Nam Su-
dc.contributor.affiliatedAuthor구남수-
dc.contributor.affiliatedAuthor염준섭-
dc.contributor.affiliatedAuthor염준섭-
dc.contributor.affiliatedAuthor정수진-
dc.contributor.affiliatedAuthor정수진-
dc.citation.volume52-
dc.citation.number2-
dc.citation.startPage281-
dc.citation.endPage304-
dc.identifier.bibliographicCitationINFECTION AND CHEMOTHERAPY, Vol.52(2) : 281-304, 2020-06-
dc.identifier.rimsid67284-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.